Tokyo, Aug. 25 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058876) titled 'Assessment of the factor of sepulcher bone separation in medication-related osteonecrosis of jaw' on Aug. 24.
Study Type:
Observational
Primary Sponsor:
Institute - Showa Medical University
Condition:
Condition - medication-related osteonecrosis of jaw
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Identification of factors causing sepulchral bone separation.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who have been or are currently receiving oral or injectable bisphosphonates, anti-RANKL antibodies, anti-sclerostin antibodies, or parathyroid hormones for the treatment of osteoporosis or bone metastasis of cancer, and who will undergo sequestrectomy with a diagnosis of MRONJ.
Key exclusion criteria - If the patient (or legal representative) does not consent to the purpose of this study.
Target Size - 10
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 06 Month 26 Day
Date of IRB - 2025 Year 06 Month 26 Day
Anticipated trial start date - 2025 Year 06 Month 26 Day
Last follow-up date - 2029 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067336
Disclaimer: Curated by HT Syndication.
